Controls serum phosphorus. ANDA 209374, held by Bionpharma. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 209374 (Sevelamer Carbonate), held by Bionpharma, was first approved by FDA on May 17, 2021, with 1 approved supplement and 0 published complete response letters.
Sevelamer carbonate for oral suspension is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 17, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sevelamer Carbonate800MG/PACKET · for suspension;oral | Sevelamer Carbonate | Rx |
| Jan 7, 2022 | Supplement 1Manufacturing | Approved | None posted |
| May 17, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters